Medical therapy: options and uses (Q37046619)

17 August 2017

Medical therapy: options and uses (English)

1 reference

17 August 2017

John D Carmichael

1

1 reference

PubMed ID

18163211

17 August 2017

Vivien S Bonert

series ordinal

2

1 reference

17 August 2017

1 March 2008

1 reference

Reviews in Endocrine and Metabolic Disorders

17 August 2017

1 reference

17 August 2017

9

1 reference

17 August 2017

1

1 reference

17 August 2017

71-81

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-007-9068-7

17 August 2017

0 references

cites work

Mechanism of estrogenic action in acromegaly

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11154-007-9068-7

Effects of tamoxifen on GH and IGF-I levels in acromegaly

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11154-007-9068-7

Consensus statement: medical management of acromegaly

21 January 2018

1 reference

12 December 2020

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

12 December 2020

Determinants of clinical outcome and survival in acromegaly

1 reference

12 December 2020

1 reference

12 December 2020

Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly

1 reference

12 December 2020

Peptides in the Brain: The New Endocrinology of the Neuron

1 reference

12 December 2020

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

12 December 2020

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

1 reference

12 December 2020

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

1 reference

12 December 2020

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

1 reference

12 December 2020

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

1 reference

12 December 2020

Model for growth hormone receptor activation based on subunit rotation within a receptor dimer

1 reference

12 December 2020

Tight control of growth hormone: an attainable outcome for acromegaly treatment.

1 reference

12 December 2020

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

1 reference

12 December 2020

Sandostatin LAR in acromegalic patients: long-term treatment

1 reference

12 December 2020

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

1 reference

12 December 2020

1 reference

12 December 2020

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

1 reference

12 December 2020

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

1 reference

12 December 2020

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

12 December 2020

Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status

1 reference

12 December 2020

Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates

1 reference

12 December 2020

Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

1 reference

12 December 2020

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

1 reference

12 December 2020

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

12 December 2020

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

12 December 2020

Successful treatment of resistant acromegaly with a growth hormone receptor antagonist

1 reference

12 December 2020

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

1 reference

12 December 2020

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

12 December 2020

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

12 December 2020

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

1 reference

12 December 2020

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

1 reference

12 December 2020

Presurgical Octreotide: treatment in acromegaly

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors

1 reference

12 December 2020

Pharmacological therapy for acromegaly: a critical review

1 reference

12 December 2020

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

1 reference

12 December 2020

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

1 reference

12 December 2020

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

1 reference

12 December 2020

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

1 reference

12 December 2020

Cabergoline treatment of acromegaly: a preliminary dose finding study

1 reference

12 December 2020

Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant

1 reference

12 December 2020

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

1 reference

12 December 2020

Epidemiology of acromegaly in the Newcastle region.

1 reference

12 December 2020

Raloxifene lowers IGF-I levels in acromegalic women.

1 reference

12 December 2020

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

1 reference

12 December 2020

Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study

1 reference

12 December 2020

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

1 reference

12 December 2020

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety

1 reference

12 December 2020

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

1 reference

12 December 2020

Raloxifene decreases serum IGF-I in male patients with active acromegaly

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

1 reference

12 December 2020

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

1 reference

12 December 2020

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

1 reference

12 December 2020

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

12 December 2020

Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls

1 reference

12 December 2020

Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant

1 reference

12 December 2020

Guidelines for acromegaly management

1 reference

12 December 2020

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients

1 reference

12 December 2020

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

12 December 2020

Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).

1 reference

12 December 2020

Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly

1 reference

12 December 2020

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

The effect of tamoxifen on GH and PRL secretion by human pituitary tumors

1 reference

12 December 2020

Treatment of acromegaly with dopamine agonists

1 reference

12 December 2020

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

1 reference

12 December 2020

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

1 reference

12 December 2020

The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.

1 reference

12 December 2020

Medical therapy for acromegaly.

1 reference

12 December 2020

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

12 December 2020

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

1 reference

12 December 2020

The pathophysiological consequences of somatostatin receptor internalization and resistance

1 reference

12 December 2020

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

1 reference

12 December 2020

1 reference

12 December 2020

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

1 reference

12 December 2020

A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

1 reference

12 December 2020

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

12 December 2020

The discovery of growth hormone-releasing hormone

1 reference

12 December 2020

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

1 reference

12 December 2020

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

1 reference

12 December 2020

Medical progress: Acromegaly

1 reference

12 December 2020

All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase

1 reference

12 December 2020

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

1 reference

12 December 2020

Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly.

1 reference

12 December 2020

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

12 December 2020

10.1007/S11154-007-9068-7

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18163211